OncoCyte Corporation (OCX): Price and Financial Metrics

OncoCyte Corporation (OCX): $2.83

0.04 (-1.39%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

F

OCX Price/Volume Stats

Current price $2.83 52-week high $4.86
Prev. close $2.87 52-week low $2.08
Day low $2.75 Volume 127,500
Day high $2.95 Avg. volume 40,856
50-day MA $2.72 Dividend yield N/A
200-day MA $3.00 Market Cap 23.41M

OCX Stock Price Chart Interactive Chart >


OncoCyte Corporation (OCX) Company Bio


OncoCyte Corporation focuses on developing diagnostic tests for the detection of breast, bladder, and lung cancers. The company was founded in 2009 and is based in Alameda, California.


OCX Latest News Stream


Event/Time News Detail
Loading, please wait...

OCX Latest Social Stream


Loading social stream, please wait...

View Full OCX Social Stream

Latest OCX News From Around the Web

Below are the latest news stories about ONCOCYTE CORP that investors may wish to consider to help them evaluate OCX as an investment opportunity.

Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays

- Significant unmet need for regulated product in $2B US testing market - Opportunity for expedited pathway for kitted product in development IRVINE, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced it has begun the FDA single-site process for its VitaGraft transplant assays. The single-site process is a well-established pathway for Lab Developed Tests (LDTs) to seek regulatory approval. This move positions Oncocyte wi

Yahoo | December 6, 2023

OncoCyte Corp (OCX) Reports Q3 2023 Financial Results with Key Product Launches on the Horizon

Strategic Focus on Upcoming Product Launches Amidst Tightened Cash Burn Management

Yahoo | November 9, 2023

Oncocyte Reports Third Quarter 2023 Financial Results

-Launching First Products in 1H 2024- -Conference Call on Thursday, November 9, 2023 at 5:00 a.m. PT / 8:00 a.m. ET- IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the third quarter of 2023, ended September 30, 2023. Third Quarter and Recent Highlights VitaGraft™ Kidney, the Company’s kidney transplant diagnostic test, received a positive coverage decision from CMS coverage; commercial re

Yahoo | November 9, 2023

Oncocyte to Announce Third Quarter 2023 Financial Results

Conference Call and Webcast on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ETIRVINE, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that the company will host a conference call and webcast on Thursday, November 9, 2023, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its third quarter financial results and recent highlights. The third quarter 2023 financial results press release will be issu

Yahoo | November 3, 2023

Oncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier

Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced the presentation of significant new clinical data at the European Society of Organ Transplant (ESOT) conference.

Yahoo | September 18, 2023

Read More 'OCX' Stories Here

OCX Price Returns

1-mo 0.00%
3-mo -6.24%
6-mo 11.86%
1-year -29.25%
3-year -97.41%
5-year -96.45%
YTD 13.20%
2023 -61.05%
2022 -85.21%
2021 -9.21%
2020 6.22%
2019 63.04%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!